頭蓋内動脈瘤の血管内治療における ENTERPRISE 2 デバイスの安全性と有効性 (EMPOWER)
ENTERPRISE 2 Vascular Reconstruction Device and Delivery System Registry: 頭蓋内動脈瘤の血管内コイル塞栓術を促進するデバイスの安全性と有効性を評価するための、多施設共同、前向き、単腕観察研究
The study is designed to evaluate the safety and effectiveness of ENTERPRISE 2 vascular reconstruction device and delivery system (hereinafter referred to as ENTERPRISE 2) to facilitate endovascular coil embolization of intracranial aneurysms.
調査の概要
詳細な説明
This is a prospective, multicenter, single-arm observational study, in which enrolled patients will be implanted with the ENTERPRISE 2 for evaluation of safety and effectiveness of ENTERPRISE 2 in real-world applications.
The study population will consist of 164 patients with ruptured or unruptured intracranial aneurysms and a parent vessel diameter of ≥2.5 mm and ≤4 mm. All patients will be implanted with the study device.
The enrolled patients will be followed at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure.
The primary endpoint is the incidence of aneurysm recanalization (at 180 days) evaluated through digital subtraction angiography (DSA). Secondary effectiveness endpoints include incidence of aneurysm recanalization (at 1 year), successful stent/coil placement rate (immediately post procedure), aneurysm occlusion (immediately post procedure, at 180 days and 1 year), incidence of retreatment (at 30 and 180 days, and 1, 2, 3, 4 and 5 years). Safety evaluation include: incidence of disabling stroke or neurological death (at 180 days and 1 year), incidence of in-stent thrombosis (at 180 days and 1 year), and incidence of in-stent stenosis (at 180 days and 1 year). Exploratory endpoints include stent wall apposition performance (intra-procedure), first-time deployment success rate (intra-procedure) and duration of stent deployment (intra-procedure).
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100070
- Beijing Tiantan Hospital, Capital Medical University
-
Beijing、Beijing Municipality、中国、100029
- Beijing Anzhen Hospital, Capital Medical University
-
-
Guangdong
-
Guangzhou、Guangdong、中国
- Zhujiang Hospital of Southern Medical University
-
-
Henan
-
Zhengzhou、Henan、中国、450052
- The first affiliated hospital of Zhengzhou university
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- Nanjing Drum Tower Hospital
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- The first affiliated hospital of Nanchang university
-
-
Liaoning
-
Shenyang、Liaoning、中国、110004
- Shengjing Hospital of China Medical University
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国
- Huashan Hospital Shanghai Medical college, Fudan University
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310007
- Zhejiang Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
This study will be conducted in patients with unruptured or ruptured intracranial aneurysm with a parent vessel diameter of ≥2.5 mm and ≤4 mm.
説明
Inclusion Criteria:
- Patient (or his/her legal representative) understands the nature of the procedure and provides voluntary written informed consent for the use of his/her peri-procedural and follow-up data;
- Aged between 18 years and 80 years of age the time of consent;
- Patient has been diagnosed with ruptured (Hunt-Hess Grade I-III) or unruptured intracranial aneurysm and requires the endovascular treatment;
- Parent vessel with a diameter of ≥2.5 mm and ≤4 mm;
- Patient is willing to return to the investigational site for the post-procedure follow-up evaluations.
Exclusion Criteria:
- Severe co-morbidity associated with a life-expectancy of less than twelve months as determined by the investigator;
- Poor clinical condition with modified Rankin Scale (mRS) score ≥4;
- Having prior or potential severe allergic reaction to contrast medium;
- Known allergies to any of the device components, including Enterprise 2 and PROWLER® SELECT™ Plus Infusion Catheter;
- Angiogram demonstrating that the aneurysm is not appropriate for endovascular treatment (i.e. severe intracranial vessel tortuosity, stenosis, intracranial vasospasm not responsive to medical therapy);
- Arteriovenous malformation (AVM) in the territory of the target aneurysm;
- Unsuitable for the antithrombotic and/or anticoagulant therapies;
- Implantation of an intracranial stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
- Implantation of a carotid stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
- Evidence of active infection;
- Pregnant or lactating women;
- Having participated in clinical studies of other investigational drugs or devices within 30 days prior to signature of Informed Consent Form, excluding epidemiological studies of observational nature or natural history or not involving intervention;
- Pre-planned staged procedure of target aneurysms.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
ENTERPRISE 2 group
The study population enrolled for this clinical study is "aneurysm patients who need stent-assisted coiling treatment", using ENTERPRISE 2 device. |
The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of aneurysm recanalization
時間枠:at 180 days post procedure
|
Incidence of aneurysm recanalization (at 180 days) = number of target aneurysm recanalization (at 180 days) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 180-day follow-up will be obtained through DSA, and the post-procedure immediate aneurysm recanalization shown in angiograms will be graded as per the Raymond-Roy Classification Scale. The Raymond-Roy Classification at each follow-up time point increased by ≥ one class relative to that immediately after the procedure is defined as recanalization (e.g., Class I immediately after the procedure, Class II at 180-day follow-up). |
at 180 days post procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of aneurysm recanalization
時間枠:at 1 year post procedure
|
Incidence of aneurysm recanalization (at 1 year) = number of target aneurysm recanalization (at 1 year) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 1 year follow-ups will be obtained through DSA or MRA or CTA. |
at 1 year post procedure
|
|
Successful stent/coil placement rate
時間枠:immediately post procedure
|
Successful stent/coil placement rate = number of target aneurysms with successful stent/coil placement ÷ total number of target aneurysms× 100%. Successful stent/coil placement is defined as successful stent deployment and successful delivery and placement of the coil at the target aneurysm assessed immediately post procedure through angiography. |
immediately post procedure
|
|
Aneurysm occlusion
時間枠:immediately post procedure, at 180 days and at 1 year post procedure
|
Aneurysm occlusion rate = number of target aneurysms with Raymond-Roy Class I or II aneurysm occlusion÷ total number of target aneurysms× 100%. The aneurysm occlusion will be assessed by classifying the post-procedure immediate aneurysm occlusion shown in angiograms based on the Raymond-Roy Classification. |
immediately post procedure, at 180 days and at 1 year post procedure
|
|
Incidence of retreatment
時間枠:at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure
|
Incidence of retreatment = number of target aneurysms receiving retreatment during the follow-up ÷ total number of target aneurysms receiving follow-up ×100%. Retreatment refers to any intervention to the target aneurysm after completing first stent-assisted coil embolization for the target aneurysm. |
at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of disabling stroke or neurological death
時間枠:at 180 days, at 1 year post procedure
|
Incidence of disabling stroke or neurological death = number of patients with disabling stroke or neurological death ÷ total number of patients receiving follow-up × 100%. Stroke is defined as rapidly developing clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours with no apparent cause other than of vascular origin, including ischemic stroke or hemorrhagic stroke (i.e., intraparenchymal hemorrhage (IPH), SAH, subdural hemorrhage (SDH), epidural hemorrhage (EDH)). Disabling stroke is defined as mRS score ≥ 3 assessed at a minimum of 90 days (+/- 30 days) post-stroke event. Neurological death, also called brain death, refers to irreversible loss of the capacity for consciousness combined with the irreversible loss of all brainstem functions, including the capacity to breathe. |
at 180 days, at 1 year post procedure
|
|
Incidence of in-stent thrombosis
時間枠:at 180 days, at 1 year post procedure
|
Incidence of in-stent thrombosis = number of target aneurysms with parent vessel (in-stent) thrombosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%. |
at 180 days, at 1 year post procedure
|
|
Incidence of in-stent stenosis
時間枠:at 180 days, at 1 year post procedure
|
Incidence of in-stent stenosis = number of target aneurysms with parent vessel (in-stent) stenosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%. Mild, moderate, and severe in-stent stenosis is clinically defined as a stenosis of <33%, 33-67%, and ≥67%, respectively, comparing with non-stented parent vessel [43, 44]. In this study, moderate and severe in-stent stenoses (with a stenosis of ≥33%) of the parent vessel are defined as in-stent stenosis. |
at 180 days, at 1 year post procedure
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Xinjian Yang, Professor、Beijing Tiantan Hospital
- 主任研究者:Shiqing Mu, Professor、Beijing Tiantan Hospital
- 主任研究者:Qingrong Zhang, Professor、The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- 主任研究者:Yuxiang Gu, Professor、Huashan Hospital Shanghai Medical college, Fudan University
- 主任研究者:Chuanzhi Duan, Professor、Southern Medical University, China
- 主任研究者:Shu Wan, Professor、Zhejiang Hospital
- 主任研究者:Bo Yu, Professor、Shengjing Hospital
- 主任研究者:Yang Wang, Professor、The First Affiliated Hospital of Nanchang University
- 主任研究者:Sheng Guan, Professor、The First Affiliated Hospital of Zhengzhou University
- 主任研究者:Wohua Zhao, Professor、Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
- 主任研究者:Xinjian Yang, Professor、Beijing Anzhen Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- CNV_2018_02
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。